Patheon Inc. (TSX: PTI) is a contract pharmaceutical company, based in Ontario, Canada. The company undertakes development, manufacturing and packaging of pharmaceutical products, both prescription (Rx) and over the counter (OTC), for a plethora of pharmaceutical, biotechnology and medical device companies, at sites in the USA, Canada, Europe and Puerto Rico.
Patheon's competitors in the contract manufacturing marketplace include Baxter and Cardinal Health, both based in the USA.
Contents |
Patheon sites have in excess of 3,000,000 square feet (280,000 m2) of manufacturing space, accommodating approximately 4600 personnel, five hundred of which are involved in pharmaceutical development activities. Patheon manufactures over 700 products for 250 clients distributed to over 150 markets. Operating revenue for 2005 was USD $698 million, 2006 $712 million and 2007 $677 million.
Patheon does not own any of the licences of the products it manufactures and is often listed as the manufacturer on packaging, with the product licence holder's brand name, product name and corporate identity being used.
Patheon's clients include many major pharmaceutical brands including Merck & Co, Novartis and Sanofi Aventis, with biotechnology customers including Amgen, and Avanir Pharmaceuticals.
Development activities are undertaken by Patheon Pharmaceutical Development Services (known as PDS), a division of Patheon Inc operating in Europe, Canada and Puerto Rico.
Patheon manufactures products in various dosage forms: oral (tablets, capsules), injectable sterile products (vials, ampoules, pre-filled syringes containing liquids, powders and lyophilisates) and topicals (creams, ointments, drops, nasal sprays, medicated and non-medicated gauze). And also medicines.